MedKoo Cat#: 408079 | Name: iRucaparib-AP6

Description:

WARNING: This product is for research use only, not for human or veterinary use.

iRucaparib-AP6 is a potent and selective small-molecule degrader of PARP1. iRucaparib-AP6 blocks the enzymatic activity of PARP1 in vitro, and PARP1-mediated poly-ADP-ribosylation signaling in intact cells. This strategy mimics PARP1 genetic depletion, which enables the pharmacological decoupling of PARP1 inhibition from PARP1 trapping. Finally, by depleting PARP1, iRucaparib-AP6 protects muscle cells and primary cardiomyocytes from DNA-damage-induced energy crisis and cell death. In summary, these compounds represent 'non-trapping' PARP1 degraders that block both the catalytic activity and scaffolding effects of PARP1, providing an ideal approach for the amelioration of the various pathological conditions caused by PARP1 hyperactivation.

Chemical Structure

iRucaparib-AP6
iRucaparib-AP6
CAS#2410557-00-3

Theoretical Analysis

MedKoo Cat#: 408079

Name: iRucaparib-AP6

CAS#: 2410557-00-3

Chemical Formula: C44H51FN6O10

Exact Mass: 842.3651

Molecular Weight: 842.92

Elemental Analysis: C, 62.70; H, 6.10; F, 2.25; N, 9.97; O, 18.98

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
iRucaparib-AP6
IUPAC/Chemical Name
2-(2,6-dioxopiperidin-3-yl)-4-((1-(4-(8-fluoro-1-oxo-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-5-yl)phenyl)-2-methyl-5,8,11,14,17-pentaoxa-2-azanonadecan-19-yl)amino)isoindoline-1,3-dione
InChi Key
CDKSZVJXSCKNQN-UHFFFAOYSA-N
InChi Code
InChI=1S/C44H51FN6O10/c1-50(27-28-5-7-29(8-6-28)40-31-11-12-47-41(53)33-25-30(45)26-35(48-40)38(31)33)14-16-58-18-20-60-22-24-61-23-21-59-19-17-57-15-13-46-34-4-2-3-32-39(34)44(56)51(43(32)55)36-9-10-37(52)49-42(36)54/h2-8,25-26,36,46,48H,9-24,27H2,1H3,(H,47,53)(H,49,52,54)
SMILES Code
O=C1NCCC2=C(C3=CC=C(CN(CCOCCOCCOCCOCCOCCNC4=C5C(N(C(C5=CC=C4)=O)C6CCC(NC6=O)=O)=O)C)C=C3)NC7=CC(F)=CC1=C72
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (PARP1 catalytic inhibition and PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is not well understood.

Preparing Stock Solutions

The following data is based on the product molecular weight 842.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Wang S, Han L, Han J, et al. Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation. Nat Chem Biol. 2019;15(12):1223–1231. doi:10.1038/s41589-019-0379-2